Olympus Scope Adverse Events in Rhode Island — What FDA Reports Reveal

Super Lawyers® 2014–2024CALL 24/7(888) 348-2735

Olympus Scope — Infection Claims

Hospitalized With an Infection After a Scope Procedure?

If you were told it was “just a complication,” Olympus’s federal guilty plea — and $85 million in penalties — tell a different story. In two minutes, you can know whether your case qualifies.

ACTIVE LITIGATION. 250+ patients · most recent filing: June 2026 · deadlines vary by state — some as short as one year.

Were you hospitalized with an infection within 30 days of an endoscopy or scope procedure?

Yes — See If My Case Qualifiesfree · takes 2 minutes
I think so / not sure

Free · confidential · no fee unless there is a recovery · answering doesn’t commit you to anything. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Prefer to talk it through? (888) 348-2735 — free and confidential.

Stefanie A. Murphy & Matthew T. Marin

Partners

You’ll get a straight answer even if it’s “you don’t qualify.” Everything you share is confidential — even if you never hire us. No fee unless there is a recovery; costs are advanced and reimbursed only out of a recovery. If you do qualify, our Olympus scope litigation team requests the medical and hospital records — you don’t chase them.

Qualification depends on what the medical records show — the scope involved, the infection, and the timing. We’ll review them and give you a straight answer either way.

Matthew T. Marin, J.D. — Admitted in Rhode Island, South Carolina, Connecticut, and Massachusetts.Stefanie A. Murphy, J.D. — Admitted in Rhode Island, Connecticut, and Massachusetts.The FDA MAUDE database contains adverse event reports from Rhode Island healthcare facilities following scope-related injuries and infections linked to Olympus devices. Marin & Murphy — Rhode Island’s home-state mass tort firm, licensed since 2008 (RI Bar #7934) — analyzes this data to identify and assist Rhode Island patients with potential claims.

Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Olympus scope claims are handled together with co-counsel, who carry principal responsibility for these matters; Marin & Murphy maintains joint responsibility. While this firm maintains joint responsibility, most cases of this type are referred to other attorneys for principal responsibility. Whether a claim is accepted is determined after review, and no attorney-client relationship is created until a written engagement agreement is signed.

What Is the FDA MAUDE Database and Why Does It Matter for RI Patients?

The FDA Manufacturer and User Facility Device Experience (MAUDE) database is a publicly accessible repository of adverse event reports submitted to the FDA by medical device manufacturers, importers, and healthcare facilities. Federal reporting obligations apply to user facilities — including Rhode Island hospitals and ambulatory surgical centers — that encounter device-related patient deaths or serious injuries. Manufacturers must report these events to the FDA, creating a searchable national database of device-related adverse events by model, facility, and event type.

For Olympus scope litigation, the MAUDE database is a critical evidentiary resource. It contains adverse event reports identifying specific Olympus device model numbers (including TJF-Q180V, TJF-160VR, TJF-160R, and related duodenoscope models), event descriptions, patient outcomes, and in many cases the reporting facility. These reports establish Olympus’s long-term notice of the contamination problem — a central issue in product liability litigation — and can corroborate individual patient claims.

Rhode Island healthcare facilities that perform ERCP and other endoscopic procedures are subject to these federal reporting obligations. MAUDE reports from Rhode Island facilities involving Olympus devices are analyzed by Marin & Murphy as part of the RI patient case evaluation process.

Rhode Island Olympus Scope MAUDE Data

Rhode Island is a small state, served by academic and community health systems that perform ERCP and other endoscopic procedures. The FDA MAUDE database contains adverse-event reports that carry Rhode Island reporter coding for Olympus duodenoscopes. Because MAUDE de-identifies the reporting user facility, these Rhode Island–coded reports do not name the hospital or health system involved, and no individual Rhode Island facility can be identified from the reports themselves.

This firm does not claim that any specific Rhode Island hospital has had an Olympus-scope adverse event or outbreak, and no named Rhode Island facility is associated with an adverse event anywhere on this page. If you underwent a scope procedure in Rhode Island and later developed an infection, this firm reviews the available MAUDE reports and other primary records as part of a case evaluation.

FDA MAUDE Data: Rhode Island-Coded Olympus Duodenoscope Reports

As of July 4, 2026, the FDA MAUDE adverse event database contains 13 Olympus duodenoscope adverse event reports carrying Rhode Island reporter coding — 9 malfunctions, 4 injuries, and 0 deaths. None of these reports identifies a specific Rhode Island hospital, because MAUDE de-identifies the reporting facility. MAUDE reports are voluntary and unverified and do not establish that an Olympus device caused any reported event; counts are reports, not confirmed injuries.

How Marin & Murphy Uses MAUDE Data for RI Patients

Matthew T. Marin, J.D. holds Rhode Island Bar #7934, admitted in 2008. Stefanie A. Murphy, J.D. is admitted in Rhode Island. The firm was founded December 4, 2008. Offices in Cranston, East Greenwich, South Kingstown, Cumberland, and Providence. Rhode Island is not a referral state for Marin & Murphy — it is the firm’s founding jurisdiction. Rhode Island patients receive direct representation from attorneys who have practiced in Rhode Island courts since the firm’s founding.

Marin & Murphy analyzes RI-specific MAUDE adverse event data as part of its intake process for Rhode Island scope infection cases. The firm uses MAUDE data to identify Rhode Island facilities where adverse events have been reported, identify specific Olympus device models associated with Rhode Island adverse events, and provide home-state context that supports Rhode Island patients’ claims. When a Rhode Island patient contacts Marin & Murphy for an evaluation, we:

1. Review available MAUDE adverse event reports from the patient’s facility involving Olympus device model numbers
2. Request procedure records identifying the specific Olympus device used and the lot/serial number
3. Cross-reference the procedure date against known Olympus contamination alerts, recalls, and field safety notices
4. Assess the patient’s infection diagnosis, treatment records, and documented outcomes
5. Evaluate the statute of limitations status under R.I. Gen. Laws § 9-1-14 (3-year personal injury SOL)

Rhode Island’s Statute of Limitations for Olympus Scope Claims

Rhode Island’s statute of limitations for personal injury is 3 years from the date of injury or discovery under R.I. Gen. Laws § 9-1-14. The SOL floor in Marin & Murphy’s intake protocol requires 90 days minimum remaining at intake (60-day workup + 30-day buffer). Contact Marin & Murphy promptly. Even if you believe your filing deadline may have passed, contact us before assuming you have no options. For wrongful death claims, Rhode Island’s wrongful death statute (R.I.

Gen. Laws § 10-7-1 et seq.) applies. The statute of limitations for wrongful death claims is also 3 years running from the date of the death. The decedent’s estate or surviving family members may pursue both wrongful death and survival action claims.

Signs a Rhode Island Patient May Qualify

Rhode Island patients should contact Marin & Murphy if they experienced all of the following:

• An endoscopic procedure — including ERCP, upper endoscopy, colonoscopy, or bronchoscopy — at any Rhode Island hospital or surgical center within the past 3 years (or earlier if the infection was only recently linked to the procedure)
• A bacterial infection diagnosed within 30–90 days of the procedure, including CRE, MDRO, sepsis, cholangitis, biliary infection, or other device-associated infection
• Medical documentation connecting the infection to the healthcare setting

Additional factors that strengthen RI claims:

• Post-procedure infection requiring hospitalization, ICU care, or prolonged antibiotic treatment
• A family member who died following a scope-related infection in Rhode Island
• Documentation from the RI facility identifying an infection control investigation
• Procedure records confirming an Olympus TJF-Q180V, TJF-160VR, or similar Olympus duodenoscope
• Rhode Island’s 3-year SOL — SOL floor at intake: 90 days minimum remaining

Frequently Asked Questions — RI MAUDE Adverse Events & Olympus Scope Claims

Related Olympus Scope Resources for RI Patients

• Rhode Island Olympus scope lawsuit — RI patient rights, direct intake, 3-year SOL.
• ERCP infection lawsuit — how bile duct procedures create contamination risk.
• CRE infection lawsuit — carbapenem-resistant infections from scope procedures.
• Sepsis after endoscopy — signs, symptoms, and legal options.
• National MAUDE adverse event analysis — national scope of Olympus MAUDE data.
• Current Olympus litigation updates — MDL formation, settlement status.